A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma
- PMID: 19100916
- DOI: 10.1016/j.ygyno.2008.10.010
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma
Abstract
Objective: We previously reported that preoperative CA-125 may predict primary cytoreductive outcome in patients with stage III ovarian carcinoma (OC). The objective of this study was to perform a contemporary analysis of the ability of CA-125 to predict cytoreductive outcome in advanced OC since our programmatic change in surgical approach that currently incorporates the utilization of extensive upper abdominal procedures, as needed, to achieve maximal cytoreduction.
Methods: We reviewed the records of all patients with advanced ovarian, tubal or peritoneal carcinoma who underwent primary cytoreduction at our institution between 1/01 and 4/05.
Results: The study cohort included 277 patients. Primary disease sites were: ovary, 232 (84%); tubal, 9 (3%); and peritoneum, 36 (13%). Stages were: IIIA, 6 (2%); IIIB, 12 (4%); IIIC, 215 (78%); and IV, 44 (16%). Tumor grades were: grade 1, 6 (2%); grade 2, 30 (11%); grade 3, 233 (84%), and undifferentiated, 8 (3%). Cytoreductive outcomes were: no gross residual disease (RD), 68 (25%); <or=1 cm RD, 153 (55%); and >cm RD, 56 (20%). There was no threshold CA-125 level that accurately predicted cytoreductive outcome. However, with CA-125 values >500 U/mL, 50% (57/113) of patients required extensive upper abdominal surgery to achieve RD <or=1 cm, compared to 27% (25/93) for those with CA-125 <500 U/mL (P=0.001).
Conclusion: Following our change in surgical paradigm that the incorporated extensive upper abdominal procedures to attain optimal debulking, preoperative CA-125 did not predict the primary cytoreductive outcome of patients with advanced ovarian, tubal, or peritoneal carcinoma. However, with a preoperative CA-125 >500 U/mL, extensive upper abdominal procedures were necessary in 50% of cases to achieve residual disease <or=1 cm. These data may be useful as part of preoperative surgical counseling and planning.
Similar articles
-
The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.Gynecol Oncol. 2008 Feb;108(2):287-92. doi: 10.1016/j.ygyno.2007.10.001. Epub 2007 Nov 13. Gynecol Oncol. 2008. PMID: 17996927
-
The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.Gynecol Oncol. 2000 May;77(2):227-31. doi: 10.1006/gyno.2000.5749. Gynecol Oncol. 2000. PMID: 10785469
-
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.Gynecol Oncol. 2004 Sep;94(3):650-4. doi: 10.1016/j.ygyno.2004.01.029. Gynecol Oncol. 2004. PMID: 15350354
-
Advanced cytoreductive surgery: American perspective.Gynecol Oncol. 2009 Aug;114(2 Suppl):S3-9. doi: 10.1016/j.ygyno.2008.11.033. Gynecol Oncol. 2009. PMID: 19573703 Review.
-
"Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary.Gynecol Oncol. 2006 Oct;103(1):329-35. doi: 10.1016/j.ygyno.2006.07.004. Epub 2006 Jul 31. Gynecol Oncol. 2006. PMID: 16876853 Review.
Cited by
-
Prognostic relevance of high pretreatment CA125 levels in primary serous ovarian cancer.Mol Clin Oncol. 2021 Jan;14(1):8. doi: 10.3892/mco.2020.2170. Epub 2020 Nov 12. Mol Clin Oncol. 2021. PMID: 33262888 Free PMC article.
-
Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer.J Cancer. 2016 Aug 11;7(13):1772-1779. doi: 10.7150/jca.15724. eCollection 2016. J Cancer. 2016. PMID: 27698915 Free PMC article.
-
The Significance of Normal Pretreatment Levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma.Rambam Maimonides Med J. 2015 Jan 29;6(1):e0005. doi: 10.5041/RMMJ.10180. eCollection 2015 Jan. Rambam Maimonides Med J. 2015. PMID: 25717387 Free PMC article. Review.
-
Correlation of Pattern of Spread and Outcomes in Advanced Epithelial Ovarian Cancers.Indian J Surg Oncol. 2018 Jun;9(2):126-132. doi: 10.1007/s13193-017-0618-5. Epub 2017 Feb 2. Indian J Surg Oncol. 2018. PMID: 29887688 Free PMC article.
-
Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.Asian Pac J Cancer Prev. 2018 May 26;19(5):1319-1324. doi: 10.22034/APJCP.2018.19.5.1319. Asian Pac J Cancer Prev. 2018. PMID: 29802693 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous